Sign inJoin waitlistJoin the waitlist

AM

Asher Marks

Director, Pediatric Neuro-Oncology · Yale-New Haven Hospital

Credentials: · ·

History

Yale-New Haven Hospital
Present

Children's National Hospital
2011–2012
Pediatrics
Children's National Hospital
2006–2009
Pennsylvania State University, Premedicine and Religious Studies
Temple University School of Medicine
2002–2006
THE PENNSYLVANIA STATE UNIVERSITY
1999–2002

Research

Postoperative Radiotherapy Patterns of Care and Survival Implications for Medulloblastoma in Young Children
JAMA Oncology · 2016 · 51 citations
Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib
Case report · Pediatric Blood & Cancer · 2018 · First of 7 authors · 33 citations
SOX2 immunity and tissue resident memory in children and young adults with glioma
Journal of Neuro-Oncology · 2017 · 30 citations

Kristopher Kahle
7 papers · 2 as a fellow
Vidya Puthenpura
7 papers
Anita Huttner
6 papers · 1 as a fellow
Michael DiLuna
6 papers
Richard Martinello
4 papers
TM
Thomas Murray
4 papers
AD
Armine Darbinyan
3 papers
Mariam Aboian
3 papers · 1 as a fellow
Ranjit Bindra
3 papers
SR
Scott Roberts
3 papers
Adam Kundishora
2 papers · 2 as a fellow
Christopher Hong
2 papers · 2 as a resident

Clinical trials

Life at 100.4: An Immersive Social Virtual Reality (VR) Education Tool for Adolescent and Young Adult Cancer Patients and Caregivers
Principal investigator · Recruiting
Yale University
2026–2027
A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss
Site PI · Recruiting · Phase 3
Children's Oncology Group
2023–2029
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
Site PI · Recruiting · Phase 1, Phase 2
National Cancer Institute (NCI)
2022–2027
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
Site PI · Recruiting · Phase 2
Children's Oncology Group
2021–2029